Cosmo Pharmaceuticals NV
Company Profile
Business description
Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology, and health tech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. The product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10, and CB-01-33.
Contact
Sir John Rogerson’s Quay
Riverside II
Dublin2
IRLT: +353 18170370
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
322
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,756.60 | 39.40 | -0.45% |
CAC 40 | 7,765.11 | 10.79 | -0.14% |
DAX 40 | 23,771.45 | 177.45 | -0.74% |
Dow JONES (US) | 42,967.62 | 101.85 | 0.24% |
FTSE 100 | 8,884.92 | 20.57 | 0.23% |
HKSE | 23,866.86 | 168.52 | -0.70% |
NASDAQ | 19,662.48 | 46.61 | 0.24% |
Nikkei 225 | 37,689.16 | 483.93 | -1.27% |
NZX 50 Index | 12,526.07 | 123.03 | -0.97% |
S&P 500 | 6,045.26 | 23.02 | 0.38% |
S&P/ASX 200 | 8,533.90 | 31.20 | -0.36% |
SSE Composite Index | 3,378.01 | 24.64 | -0.72% |